Skip to Content
menu

Change Life Stories

Shanna, Oren and Damian Living with Hereditary Angioedema Type 1

There’s so much uncertainty with rare disease — the best treatment is your own confidence in making the decisions that are right for you.

Read Shanna's story

News Updates

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

Read more

Intellia Therapeutics Announces First Quarter 2025 Financial Results and Highlights Recent Company Progress

Read more
View all news updates

Aiming to make the impossible, possible

Our
Mission

Transforming lives of people with severe diseases by developing potentially curative genome editing treatments.

Learn more

Programs
and Pipeline

Each one of us together for patients

Learn more

Full-Spectrum Approach

Opening a new era in medicine

Learn more

Join Us

See how you can change life stories with genome editing.

Learn more